Edition:
United States

Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

3.16USD
14 Dec 2017
Change (% chg)

$0.01 (+0.32%)
Prev Close
$3.15
Open
$3.19
Day's High
$3.40
Day's Low
$3.07
Volume
140,497
Avg. Vol
70,136
52-wk High
$3.40
52-wk Low
$1.11

Latest Key Developments (Source: Significant Developments)

Sierra Oncology reports net loss $0.19 per share
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Sierra Oncology Inc ::Sierra Oncology reports third quarter results.Qtrly ‍net loss per share, basic and diluted $0.19​.  Full Article

Sierra Oncology reports qtrly loss per share $‍0.20​
Thursday, 10 Aug 2017 07:00am EDT 

Aug 10 (Reuters) - Sierra Oncology Inc :Sierra Oncology reports second quarter 2017 results.‍on track to provide preliminary update from CHK1 inhibitor SRA737 clinical trials in early 2018​.‍$116.7 million cash at June 30, 2017 projected to fund current operating plans through approximately mid-2019​.Qtrly loss per share $‍0.20​.  Full Article

Sierra Oncology reports initial progress from phase 1 clinical trials of CHK1 inhibitor SRA737
Monday, 5 Jun 2017 07:00am EDT 

June 5 (Reuters) - Sierra Oncology Inc :Sierra oncology reports encouraging initial progress from ongoing phase 1 clinical trials of chk1 inhibitor sra737.Sierra oncology inc says sra737 has been well-tolerated to date.Sierra oncology inc - "no grade 2 or higher sra737-related adverse events have been reported".Sierra oncology inc says for phase 1 chemotherapy combination study, has concluded enrolment and study has transitioned to stage 2.Sierra oncology inc - sra737 development program remains on track.  Full Article

Sierra Oncology granted U.S., EU patents for CHK1 inhibitor SRA737
Tuesday, 30 May 2017 07:00am EDT 

May 30 (Reuters) - Sierra Oncology Inc :Sierra Oncology granted U.S. and EU patents for CHK1 inhibitor SRA737.  Full Article

Sierra Oncology Receives clearance to enhance ongoing clinical trials for SRA737
Wednesday, 10 May 2017 07:00am EDT 

May 10 (Reuters) - Sierra Oncology Inc : :Says received clearance from regulators in UK to amend two ongoing phase 1 trials for its CHK1 inhibitor, SRA737.Sierra Oncology Receives clearance to enhance ongoing clinical trials for SRA737.Says amended trials will include cohort expansions of prospectively selected patients with tumors.Says an initial update from these trials is anticipated in early 2018.Says study will now consist of two phases, a dose escalation phase and a cohort expansion phase, being run concurrently.  Full Article

Sierra Oncology Inc Q1 net loss per share $0.26
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Sierra Oncology Inc :Sierra Oncology reports first quarter 2017 results.Sierra Oncology Inc - qtrly net loss per share $0.26.Q1 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Sierra Oncology - believes its existing cash and cash equivalents will be sufficient to fund current operating plans through approximately mid-2019.  Full Article

Sierra Oncology Inc - Q4 net loss per share attributable to common stockholders $0.30
Thursday, 2 Mar 2017 07:00am EST 

Sierra Oncology Inc : Sierra Oncology reports 2016 year-end results . Sierra Oncology Inc -" existing cash and cash equivalents will be sufficient to fund our current operating plans through approximately mid-2019" .Sierra Oncology Inc - qtrly net loss per share attributable to common stockholders $0.30.  Full Article

Frazier Healthcare VI L.P. reports 16.28 percent stake in Sierra Oncology as on Feb 14 - SEC filing
Friday, 24 Feb 2017 03:37pm EST 

Sierra Oncology Inc :Frazier Healthcare VI L.P. reports 16.28 percent stake in Sierra Oncology as on February 14, 2017 - sec filing.  Full Article

Sierra Oncology says public offering of 19.5 mln shares priced at $1.35/shr
Thursday, 9 Feb 2017 09:11am EST 

Sierra Oncology Inc : Sierra oncology announces pricing of public offering of common stock . Says public offering of 19.5 million common shares priced at $1.35per share .Says public offering of 19.5 million common shares priced at $1.35per share.  Full Article

Sierra Oncology announces proposed public offering of common stock
Wednesday, 8 Feb 2017 04:01pm EST 

Sierra Oncology Inc :Sierra Oncology announces proposed public offering of common stock.  Full Article

BRIEF-Sierra Oncology reports net loss $0.19 per share

* Qtrly ‍net loss per share, basic and diluted $0.19​ Source text for Eikon: Further company coverage: